Liquenia® Treatment Results
The results of Liquenia® Treatment are assessed using objective clinical variables: symptoms, signs, histology, and quality of life. We do not work with subjective impressions—we document what happens and publish it.
How we measure results
In our protocol, outcome assessment is systematic and integrated into the 12-month follow-up. We use three types of measures:
> Symptom variables. We assess the intensity of itching, burning, dyspareunia, and vulvar pain using validated scales at each clinical review. The goal is to document objective progression, not only subjective perception.
> Clinical and examination variables. At each review, we assess the visible signs of VLS: extent of whitish lesions, presence of erosions or fissures, degree of atrophy, and anatomical changes. Direct examination is the most reliable tool for assessing tissue response.
> Histological variables. When indicated, we perform a comparative biopsy 3 months after the procedure. Comparing the pre- and postoperative biopsies allows us to document changes at the cellular and tissue level—the most objective way to confirm that the tissue is responding to treatment.
> Quality of life variables. We use validated questionnaires to measure the impact of VLS on sexual function, sleep, emotional state, and daily activities before and after treatment.
When are results noticed?
Response to Liquenia® Treatment follows a progressive pattern. Each patient progresses individually, but these are the typical timelines we observe in clinic:
Weeks 1–2
Local recovery
Post-procedure discomfort—mild swelling and sensitivity in the treated area—resolves in the first or second week. This is not the time to assess therapeutic results.
Weeks 4–8
First symptomatic improvements
Most patients begin to notice reduced itching and burning during this period. Improvement is gradual—not an abrupt change, but a progressive decrease in the intensity and frequency of symptoms.
Month 3
Interim assessment
We perform a complete clinical review. If a comparative biopsy was indicated, histological results are available at this time. Many patients report significant improvement in dyspareunia and in vulvar tissue quality.
Month 12
End-of-cycle assessment
This is the time for a full assessment of the treatment cycle. We evaluate the overall response, adjust the maintenance protocol, and decide whether a second session is indicated.
Documented areas of improvement
These are the variables in which we document improvement in our patients:
Vulvar itching (pruritus)
Pruritus is the most common and disabling symptom of VLS. Reducing itching is also the improvement with the greatest impact on patients’ day-to-day and nighttime quality of life.
Vulvar burning and pain
Burning at rest and pain with clothing or when sitting—which many patients have suffered for years—improve progressively from the first weeks.
Erosions and fissures
Erosive lesions and recurrent fissures—a constant source of pain and bleeding—decrease in frequency and severity. The tissue regains resilience and healing capacity.
Vulvar tissue quality
Comparative biopsies document histological changes: reduced fibrosis, increased epithelial thickness, and improved vascularization. Changes that corticosteroids alone do not produce.
Sexual function
Dyspareunia—pain during sexual intercourse—improves significantly in most patients, with recovery of introital elasticity and reduced pain sensitivity.
Emotional well-being
Although it is not a direct clinical variable, the impact on emotional well-being is consistent: reducing physical symptoms improves sleep, relationships, and self-esteem. We see it at every review.
What the research says
The results of Liquenia® Treatment are not based solely on the clinical experience accumulated in our practice. They are supported by clinical research published in international peer-reviewed scientific journals.
The study published in Aesthetic Surgery Journal in 2025—resulting from the research program launched in 2017 with the support of Hospital Universitario La Fe and the La Fe Health Research Institute in Valencia—documents the efficacy and safety of the Liquenia-SVF protocol in patients with vulvar lichen sclerosus, with 12-month follow-up.
The results of that work showed significant improvement in the main VLS symptoms, favorable histological changes documented on comparative biopsy, and an excellent safety profile with no relevant complications during the follow-up period.
In 2025, the protocol was included in the Clinical Practice Guideline of the International Society of Aesthetic Plastic Surgery (ISAPS), representing formal recognition by a leading international scientific society.
*Individual results may vary. Clinical improvement depends on the stage of the disease, each patient’s individual response, and adherence to the maintenance protocol. Liquenia® Treatment does not guarantee complete or permanent remission of vulvar lichen sclerosus.*
How long do the results last?
One of the most common questions we receive is whether the results of Liquenia® Treatment are maintained over time. The honest answer is that VLS is a chronic disease and that most patients require an ongoing maintenance protocol.
What we do document is that the improvement achieved with Liquenia® Treatment is sustained throughout the 12-month follow-up period in the vast majority of treated patients. From that point on, individualized follow-up allows us to adapt the maintenance protocol—which typically combines lower-dose corticosteroids with periodic reviews—to each patient’s specific course.
In some cases, a second Liquenia® Treatment session may be indicated depending on the course. This decision is always made on an individual basis, based on clinical examination and response to the previous treatment.
Results are individual. So is the assessment.
There is no universal response to Liquenia® Treatment. What does exist is an honest clinical assessment of your case, so you know what you can realistically expect before making any decision. That is what we offer in our assessment consultation.